Kornimate/medical-research-clean huggingface dataset:
mco membrane efficiency in septic shock patients

Conditions: Septic Shock; Acute Kidney Injury

Summary: this is a monocentre randomized pilot study. all patients received two consecutive rrt: cvvhd with mco filter (ultraflux® emic®2) and post-continuous veno-venous hemodiafiltration (cvvhdf) with hff(av1000s®) in a controlled randomized (1:1) blinded manner. crossover randomized to sequence (a+b or b+a) for 48 h total without washout.

this is a monocentre randomized pilot study. all patients received cvvhd with mco filter (ultraflux® emic®2) and post-continuous veno-venous hemodiafiltration (cvvhdf) with hff(av1000s®) in a controlled randomized (1:1) blinded manner. crossover randomized to sequence (a+b or b+a) for 48 h total without washout. the efficiency of the filters for small and middle molecules was compared in septic shock patients with aki stage 3.

Eligibility criteria:
inclusion criteria: * age \> 18 years; * septic shock according to accp/sccm criteria * aki kdigo stage 3 * clinical decision to begin citrate based-rrt for at least 48 hours * hb \>= 9 g/dl * obtain the informed consent exclusion criteria: * pre-existing chronic renal insufficiency * weight \> 125 kg life expectancy \<24 hr * declared do not resuscitate or comfort measures * platelets \< 20 \[10\^3/ul\] or active bleeding * pregnancy * contraindication to citrate

Keywords: renal replacement therapy, cytokines efficiency
scalp care efficacy evaluation for premium scalp revitalizing essence

Conditions: Scalp Health; Hair Condition; Hair Loss; Sebum Production; Hair and Scalp Health

Summary: the study aims to evaluate the efficacy of the premium scalp revitalizing essence on human scalp skin. a total of 60 healthy adults, aged 18 to 60, will be recruited and randomly assigned into five groups receiving different formulations. participants will use the product once daily for 56 days, and their scalp conditions will be assessed through skin texture tests at multiple time points. key parameters such as sebum content, overall hair loss, hair density, scalp condition, and hair length will be measured.

this is a prospective, randomized, open-labeled study to investigate the effects of premium scalp revitalizing essence on changes in the skin texture of human scalp skin. sixty healthy adults aged from 18 to 60 will be recruited and randomly assigned into five groups, with 12 individuals in each group. group 1 uses negative control; group 2 uses the base formula (including active ingredient panthenol \[vit. b5\]); group 3 uses base + igf-1 \& fgf-7; group 4 uses base + centella asiatica extracellular vesicles; group 5 uses base + centella asiatica exosome + igf-1 \& fgf-7. before using the test product, all 60 participants undergo the first scalp skin texture test. after 14 days of using the test product, a second scalp skin texture test is conducted; after 28 days of use, a third test is performed; after 42 days of use, a fourth test is conducted; and after 56 days of use, a fifth test is carried out. the scalp skin texture tests include measurements of skin (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. the sebumeter® sm815 probe of the mpa580 device and the scalpx intelligent scalp diagnostic system will be used to measure the parameters of the study.

Eligibility criteria:
inclusion criteria: * healthy adults of any gender from the age of 18 to 60 years (inclusive). * absence of chronic diseases, major illnesses, or allergies. * major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coro-nary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant exclusion criteria: * currently taking any medication or using any scalp care products

Keywords: scalp care hair loss skin texture sebum measurement scalp condition hair length hair density cosmetics product formulation growth factor centella asiatica extracellular vesicles
objective integrated multimodal electrophysiological index for the quantification of visceral pain

Conditions: Abdominal Pain

Summary: the objectives of the study are to 1) conduct telemetric biosignals (eda, ecg, and emg) recording in healthy controls and ibs participants experiencing cutaneous and visceral pain; and 2) validate the oime index as a biomarker for quantifying pain in ibs participants and its capability to assess the treatment of ibs pain via an ambulatory trial.

in part 1, data collection for training the oime model, we will collect autonomic and muscular activities with integrated biosignal device and visceral pain level in both healthy controls and ibs participants. these data will be used to train a machine learning model to produce an objective integrated multimodal electrophysiological (oime) index. in part 2, the ambulatory trial, we will collect data to validate the oime index as a biomarker of pain in ibs participants. we will run an ambulatory trial to validate the oime index as a biomarker to assess the treatment of ibs pain.

Eligibility criteria:
inclusion criteria: * participants need to be diagnosed with ibs by a healthcare provider according to rome-iii or -iv criteria, with a current report of abdominal pain. * men and women 18-50 years old * able to read and speak english * daily access to a computer with internet access. exclusion criteria: * other chronic pains that are usually not comorbid with ibs, e.g., diabetic neuropathy, myofascial pain, low back pain, peripheral neuropathy etc. * celiac disease or inflammatory bowel disease * diabetes mellitus; d) serious mental health conditions * women during pregnancy or within 3 months post-partum period * self- reported regular use of opioids or other illicit substances. * participants who have had covid-19 should be fully recovered, and will be asked if their medical provider has made any restriction on activities.

Keywords: visceral pain irritable bowel syndrome autonomic and muscular activities biosignals personalized pain self-management
speech-to-speech voice-cloning care (svcc) to improve icu-acquired anxiety for critically ill patients

Conditions: Critical Care Nursing

Summary: the goal of this clinical trial is to learn the effect of speech-to-speech voice-cloning care (svcc) on improving icu-acquired anxiety for critically ill patients. the main question it aims to answer is: * can the use of participants' loved ones' voices by nurses in communication while providing care lead to better mental health and clinical outcomes? researchers will see if the implementation of svcc can reduce anxiety and depression, and improve clinical outcomes. participants will: * receive the svcc intervention until the endotracheal tube (ett) is removed. * keep a diary of delirium, the duration of mechanical ventilation, and icu stays.

during the svcc, healthcare will be delivered by nurses who will communicate with participants using the familiar voices of their loved ones, transformed in real-time by an artificial intelligence voice-cloning tool.

Eligibility criteria:
inclusion criteria: * expected mechanical ventilation time \> 24 hours; * expected icu stay \> 72 hours; * language: chinese; * richmond agitation-sedation scale (raas) score ≥ -2 points; * hemodynamic stability. exclusion criteria: * severe hearing impairment or worse (grade 3 or higher according to who's grades of hearing impairment); * disorders of consciousness or comprehension; * mental or psychological disorders that are being treated with medication; * head trauma or surgery resulting in an inability to wear earphones.

Keywords: icu-acquired anxiety voice-cloning critical care nursing family-centered care artificial intelligence
hiv prevention intervention for people living with hiv/aids

Conditions: HIV Infections

Summary: hiv prevention interventions are needed to assist people living with hiv/aids to adhere to their medications and not transmit the virus to others. this study is testing a behavioral intervention designed to address both medication adherence and risk reduction in people living with hiv/aids. it is hypothesized that the experimental behavioral intervention will show improved medication adherence and safer sexual behaviors compared to a comparison group.

non-adherence to antiretroviral medications can lead to the development of treatment resistant genetic variants of hiv which can then be transmitted to sexual risk partners. interventions are urgently needed to reduce the risk of hiv treatment resistance and the risks of transmitting hiv. this application proposes to test a theory-based behavioral intervention to simultaneously improve hiv treatment adherence and reduce hiv transmission risk behaviors in people living with hiv-aids. grounded in behavioral theory, the experimental intervention will be delivered in a mixed format model with five group sessions preceded by and followed by one individual counseling session conducted by community-based group facilitators. the intervention will be conducted at an aids service organization in atlanta. men and women will be recruited from a variety of aids services and infectious disease clinics. following informed consent and baseline assessments participants will be randomly assigned to receive either the (a) integrated hiv treatment adherence - risk reduction intervention or (b) a time-matched sexual risk reduction intervention, or (c) a time matched non-contaminating comparison intervention. participants will be followed over the course of a 9-month observation period. assessments will include measures of information, motivation, and behavioral skills pertaining to hiv treatment adherence and hiv transmission risks and risk reduction, medication adherence, sexual transmission risk behaviors, viral load, and cd4 cell counts. the study will test the hypothesis that a unified, integrated theory-based hiv treatment and risk reduction intervention will improve hiv treatment adherence, reduce hiv transmission risk behaviors, and improve health as indexed by viral load and cd4 cell counts. the study will also examine the influence of theoretical constructs on intervention outcomes. the intervention under investigation will be among the first to simultaneously address treatment adherence and risk behavior in an integrated model derived from a single, unified theory of health behavior. if shown effective, the intervention model will be ready for immediate dissemination to community services for people living with hiv-aids.

Eligibility criteria:
inclusion criteria: * age 18 years or older, * tested hiv positive, * able to provide informed consent. exclusion criteria: * significant cognitive impairment.

Keywords: hiv prevention treatment adherence treatment for prevention
the swedegraft right-heart-substudy

Conditions: Coronary Artery Bypass Surgery; Right-Sided Heart Failure

Summary: background right ventricular dysfunction is a common echocardiographic finding after cardiac surgery. pericardial disruption has been suggested as the most probable cause as the phenomenon occurs within minutes after pericardial incision. the investigators suspect that validated two-dimensional echocardiographic measures for right ventricular function might not reflect the altered rv contraction pattern including paradoxical interventricular septal motion and reduced long-axis function following open cardiac surgery. the present study aims to determine the prevalence and scale of right ventricular dysfunction two years after cabg by applying the latest available two- and three-dimensional echocardiographic technology in right ventricular evaluation. in addition, the investigators investigate the impact of right ventricular dysfunction on functional outcome. methods the right-heart-study is an observational substudy of the swedegraft trial at aarhus university hospital in denmark. swedegraft is a nordic, multicenter, prospective, randomized, register-based, clinical trial (clinicaltrials.gov identifier: nct03501303; ragnarsson 2020). patients for the current right-heart-substudy will be recruited amongst the 269 patients included in the swedegraft trial at aarhus university hospital from 10 september 2018 to 25 may 2020. patients are enrolled at the time of swedegraft follow-up with cardiac-ct (approximately 30 months after cabg). after written informed consent, we perform additional full 2d and 3d echocardiography with special focus on rv function, collect patient-reported data on functional outcome, and measure brain natriuretic peptide and hemoglobin levels.

complete study protocol attached

Eligibility criteria:
inclusion criteria: swedegraft inclusion criteria: * first-time non-emergent cabg patients * need for at least one vein graft * able to provide informed consent and accepted for isolated primary cabg. additional inclusion criteria for the right-heart-substudy: • ability to meet for follow-up visit exclusion criteria: swedegraft exclusion criteria: * no greater saphenous vein grafts available (previous vein stripping or poor vein quality) * age \> 80 years at the time of inclusion * allergy to contrast dye * renal failure with egfr \<15 ml/min at primary inclusion * coagulation disorders * excessive risk of wound infection * participation in other interventional trial on grafts * any condition that seriously increases the risk of non-compliance or loss of follow-up * pregnant women or women of child bearing potential without negative pregnancy test additional inclusion criteria for the right-heart-substudy: • inability to cooperate to transthoracic echocardiography

Keywords: 2-d echocardiography 3-d echocardiography coronary artery bypass surgery right-sided heart failure patient reported outcome measures
effect of preoperative information about pain on postoperative pain experience and patient satisfaction

Conditions: Post Operative Pain

Summary: patients are randomized into 2 groups. the intervention group which receives preoperative counseling about pain and a control group which does not receive this counseling. the patients are followed up looking at pain scores and pain experience and satisfaction with pain management for 2 days post operative.

* all patients admitted for elective upper and lower limb surgery, will be expected to have a preoperative visit by the anesthetic provider on the day before surgery. * those who will have consented to participate in the study will be randomized to either the intervention or control group. * the intervention group will receive specific preoperative information about pain in private by the principal investigator in addition to the preoperative assessment. * the following variables will be recorded preoperatively: socio-demographics (age, gender, tribe, education level) and vital signs (pulse rate, blood pressure and oxygen saturation). * a numerical pain score will be explained to patient before it is recorded preoperatively. * the patient will also be informed that the pain scores will be repeated after surgery at (someone will take the pain scores again after surgery at) 0, 6, 12, 24, 48hours or till discharge if less than 48hours. in addition the pulse rate, number of analgesic intravenous/ intramuscular injections or tablets needed/or given will be recorded. * assessed pain will be classified as no pain (1-3), pain (4-10) but also as no pain (0), mild (1-3), moderate (4-6) and severe pain (7-10). * intra operatively, the anaesthetic technique (general or regional), medications given, duration of surgery will be recorded in) the questionnaires.

Eligibility criteria:
inclusion criteria: * age of 18 years and above * elective orthopedic surgery patients admitted to orthopedic/trauma ward mulago hospital * patient who gives consent exclusion criteria: * patients with chronic pain not related to the surgery they are to undergo * patients with bone cancer * inability to speak or hear (deaf or dumb) * previously recruited but comes for re-surgery for same condition
a study on efficacy and safety of topiramate in treatment of obese subjects with dyslipidemia

Conditions: Obesity; Hyperlipidemia; Hypertriglyceridemia

Summary: the purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.

topiramate is not approved for the treatment of obesity. studies have shown that topiramate reduces weight in obese patients with or without type 2 diabetes, and may have the adjunctive benefit of reducing triglyceride and cholesterol levels in these patients. this double-blind, placebo controlled study evaluates the long-term efficacy of topiramate for reduction of weight and triglyceride levels in obese patients with borderline to high hypertriglyceridemia, and the safety and tolerability of topiramate in this patient population. the study consists of four phases: 4-week enrollment (screening) phase, 8-week titration phase (topiramate dose will be increased from 16mg/day to the assigned dose), 52-week maintenance phase, and 6-week follow-up. effectiveness of topiramate will be evaluated by multiple measurements such as change in body weight, body mass index, fasting serum triglyceride levels, cholesterol and other lipid profiles. safety evaluations will include incidence/severity of adverse events, vital signs, clinical laboratory results. the hypothesis is that topiramate as compared to placebo will provide a greater percent reduction in body weight and in fasting serum triglycerides from week 0 (baseline) to week 60. after the initial 8-weeks titration phase, the patients will be randomized to receive either 96mg (48mg twice daily) or 192mg (96mg twice daily) topiramate or placebo (twice daily) by mouth for 52 weeks.

Eligibility criteria:
inclusion criteria: * a body mass index (bmi) \>= 27 kg/m\^2 and \<50 kg/m\^2 * stable weight at least four months prior to the first enrollment visit * diagnosis of dyslipidemia (serum triglycerides representative of mild to moderate hypertriglyceridemia and low hdl or high ldl) * patients on lipid lowering medication should be on monotherapy with the same drug for at least 4 months and on the same dose for at least 2 months prior to the first enrollment * female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test) exclusion criteria: * contraindication or hypersensitivity to topiramate * pregnancy, nursing or women who plan to become pregnant during the study * enrollment fasting triglycerides \ = 1000 mg/dl, and/or ldl \>= 190 mg/dl * hyperlipidemia secondary to known disease * other significant medical conditions such as cardiovascular or liver disease

Keywords: obesity dyslipidemia hyperlipidemia triglyceride hdl ldl diabetes
effects of exercise or taping on pain, function, range of motion, strength and kyphosis in subacromial pain syndrome

Conditions: Subacromial Impingement Syndrome; Exercise Addiction; Shoulder Pain

Summary: participants with subacromial pain syndrome underwent shoulder exercises. in addition to the exercises, group a received thoracic extension exercise and group b received kinesio taping. all exercises were performed five days per week for three weeks. thoracic extension exercise was performed once a week and remained in place for 5 days. evaluations were performed one to three days before and one to three days after the three-week exercise program.

seventy-five adults with subacromial pain syndrome were randomized into three groups. group a and group b received thoracal extension exersice and thoracal kinesiotaping in addition to shoulder exercise, respectively, while group c received only shoulder exercise. all exercises were performed five days a week for three weeks. thoracal extension exercise was applied once a week and remained in place for 5 days. assessments were conducted one to three days before and one to three days after the three-week exercise program. shoulder pain intensity, pressure pain threshold (ppt) of the upper trapezius and pectoralis major, self-reported function and health status, active range of motion (arom), and isometric strength of the shoulder were assessed.

Eligibility criteria:
inclusion criteria: * having shoulder pain for at least 6 weeks * aggravation of shoulder pain with resisted shoulder movements exclusion criteria: * those with full-thickness rotator cuff rupture * those who have had previous shoulder surgery * those who have had cervical or thoracic spine surgery * those with a history of inflammatory disease or cancer

Keywords: shoulder pain shoulder function shoulder exercise kinesio taping thoracic exercise thoracic posture
feasibility study of the magnetic anal sphincter (fenix system)

Conditions: Fecal Incontinence

Summary: the purpose of this feasibility study is to obtain preliminary safety and effectiveness information and develop procedural optimization for the magnetic anal sphincter device (fenix system) in reinforcement of anal sphincter function to treat severe fecal incontinence (fi).

study subjects followed to 12 months post implant outside the u.s. study subjects followed to 5 years post implant in the u.s.

Eligibility criteria:
inclusion criteria: * age ≥ 19 years, \ 3yrs. * documented history of severe fecal incontinence for at least 6 months * subject diary documents ≥ 2 episodes per week on average over diary period, leakage greater than seepage * subject has failed standard conservative and medical therapy * subject is a surgical candidate. * subject is willing and able to cooperate with follow-up examinations. * subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes. exclusion criteria: * subject has history of significant obstructed defecation or other significant chronic defecatory motility disorders * subject has current, external full thickness rectal prolapse or vaginal prolapse * subject has an electric or metallic implant within 10cm of the area of device placement * subject has inflammatory bowel disease * subject has irritable bowel syndrome * subject has systemic disease as source of fi (scleroderma, neurologic disorders, crohn's) * subject has active pelvic infection * subject has chronic diarrhea * subject diagnosed with anal, rectal, or colon cancer within 2 years * subject has had prior anterior resection of the rectum * subject has undergone pelvic radiation therapy * subject has significant scarring of the recto-vaginal septum, a permanent implant in the recto-vaginal septum, or a history of recto-vaginal fistula * subject has had previous anorectal posterior compartment surgery * the procedure is an emergency procedure * subject is currently being treated with another investigational drug or investigational device. * subject cannot understand trial requirements or is unable to comply with follow-up schedule. * subject is pregnant or nursing, or plans to become pregnant. * subject has history of complex anal fistula

Keywords: fenix